May 19, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Brepocitinib approval for dermatomyositis would be ‘highlight of the derm-rheum world’
DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according to a speaker at the Congress of Clinical Rheumatology East.“A true highlight of the derm-rheum world is that we finally will have an FDA-approved therapy that is modern, targeted and effective in both skin and muscle disease of dermatomyositis,” said
601 words~3 min read
